Haemophilia A is an X-linked bleeding disorder caused by deficiency of coagulation factor VIII, with severe disease carrying high risks of joint bleeding and disability. Extended half-life factor concentrates and non-factor haemostatic agents, most notably emicizumab, have transformed prophylaxis management. Gene therapy clinical programmes are delivering durable factor expression and approaching regulatory submission.
Hemophilia Normalization's Price Tag and Policy Implications
Achieving 'normalization' in hemophilia care, while improving patient outcomes, introduces substantial financial burdens on healthcare systems. Payers must grapple with the high costs of novel therapies and ensure equitable access.
Moving Beyond Deficiencies: Normalization Strategies in Hemophilia Care
The concept of 'normalization' in hemophilia care shifts the focus from merely preventing bleeds to enabling patients to live full, unrestricted lives. Clinicians need to proactively address lifestyle goals, activity levels, and psychosocial well-being in a...